JRCT ID: jRCT2080225346
Registered date:25/08/2020
Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination with Ibrutinib in Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma [M20-075]
Basic Information
| Recruitment status | completed |
|---|---|
| Health condition(s) or Problem(s) studied | |
| Date of first enrollment | 04/09/2020 |
| Target sample size | 12 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Venetoclax Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
| Primary Outcome | efficacy |
|---|---|
| Secondary Outcome | safety efficacy pharmacokinetics other |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | |
| Exclude criteria |
Related Information
| Primary Sponsor | |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | NCT04477486,JapicCTI-205442 |
Contact
| Public contact | |
| Name | |
| Address | |
| Telephone | +81-120-587-874 |
| Affiliation | |
| Scientific contact | |
| Name | |
| Address | |
| Telephone | |
| Affiliation | AbbVie G.K |